Cover Image


Inhaled Drug Delivery to 2022

出版商 Greystone Research Associates 商品編碼 228360
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
Back to Top
吸入型給藥:設備、適應症、治療、預測 Inhaled Drug Delivery to 2022
出版日期: 2015年03月16日 內容資訊: 英文


第1章 摘要整理

第2章 吸入型藥物市場

  • 治療標的
  • 上氣道
  • 全身性吸入遞送(給藥)
  • 需求促進要素
  • 危險因素

第3章 競爭技術

  • 乾粉吸入劑
  • 定量吸入器
  • 噴霧器

第4章 吸入技術與產品開發因素

  • 製劑設計因素
  • 製劑
  • 製劑技術
  • 賦形劑與放出簡介

第5章 吸入器設計因素

  • 乾粉吸入劑
  • 定量吸入器
  • 噴霧器

第6章 吸入器的性能因素

  • 生物有效性
  • 容量再現性
  • 活性化合物的穩定性
  • 實驗與包裝

第7章 吸入器;產品及設備的評估

  • 乾粉吸入劑
  • 定量吸入器
  • 噴霧器

第8章 吸入藥物:治療部門分析及預測

  • 呼吸系統的適應症
  • 氣喘
  • 慢性阻塞性肺病
  • 全身性藥物遞輸
  • 生物恐怖行動
  • 循環系統系內科
  • 肺高血壓
  • 糖尿病
  • 遺傳性疾病
  • 囊狀纖維化症
  • 免疫學
  • 感染疾病
  • 骨質疏鬆症
  • 神經學
  • 腫瘤學

第9章 市場因素

  • 法規問題
  • 病人依從性
  • 醫療經濟學
  • 相關設備

第10章 市場各部門主要企業簡介



The upper airway diseases Asthma and COPD remain significant health challenges for both patients and clinicians. Inhalers that combine two drugs indicated for treating upper airway diseases in one inhaler are gaining interest due to the complementary therapeutic effects of certain classes of drugs when taken together. Systemic delivery continues to represent an area of significant opportunity. Products and product candidates in this category include inhaled drugs for the treatment of such diverse conditions as pulmonary arterial hypertension, neurological disorders, hereditary diseases and pain management.

What You Will Learn

  • Which therapeutic drugs are delivered via aerosol inhalers, dry powder inhalation and nebulizers for upper respiratory conditions? For systemic delivery?
  • What are the inhalable drugs currently in development, their formulation and device strategies, and targeted indication(s) and what are market prospects?
  • What are the key inhalation device technologies for commercial and development-stage devices, and what are the product technology issues and related market factors?
  • What are the current market dynamics of inhaled drug targeted disease segments, and what are the growth prospects and market potential for inhaled therapeutic drugs?
  • What is the current market share for inhaled drugs by product? By supplier? What will it be in seven years?
  • Who are the Inhaled drug product market participants, their products, market strategies, product development activity, and partners?

Table of Contents

  • Executive Summary
  • The Orally Inhaled Drug Delivery Market
  • Therapeutic Targets
  • Upper Respiratory
  • Systemic Inhaled Delivery
  • Demand Drivers
  • Risk Factors
  • Competing Technologies
  • Dry Powder Inhalers
  • Metered Dose Inhalers
  • Nebulizers
  • Inhalation Technology & Product Development Factors
  • Formulation Factors
  • Drug Formulations
  • Formulation Technologies
  • Excipients and Release Profiles
  • Inhalation Device Design Factors
  • Dry Powder Inhalers
  • Metered Dose Inhalers
  • Nebulizers
  • Inhaler Performance Factors
  • Bioavailability
  • Dose Reproducibility
  • Active Compound Stability
  • Testing and Packaging
  • Inhalation Devices - Product & Device Assessments
  • Dry Powder inhalers
  • Metered Dose Inhalers
  • Nebulizers
  • Inhaled Drugs - Therapeutic Segment Analysis & Forecasts
  • Upper Respiratory Indications
  • Asthma
  • COPD
  • Systemic Drug Delivery
  • Bioterror
  • Cardiovascular Medicine
  • Pulmonary Hypertension
  • Diabetes
  • Hereditary Diseases
  • Cystic Fibrosis
  • Immunology
  • Infectious Diseases
  • Osteoporosis
  • Neurology
  • Oncology
  • Market Factors
  • Regulatory Issues
  • Patient Compliance
  • Healthcare Economics
  • Connected Devices
  • Market Sector Company Profiles
Back to Top